Neonatal Infectious Diseases. Evaluation of Neonatal Sepsis.

Pediatric Clinics of North America

Volumn 60, Issue 2, 2013, Pages 367-389

  Camacho Gonzalez, Andres ^a   Spearman, Paul W ^a   Stoll, Barbara J ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Children's Healthcare of Atlanta at Egleston   (United States)

Author keywords

Biologic markers; Early and late onset disease; Immature immunity; Neonatal sepsis; Treatment

Indexed keywords

AMPHOTERICIN; AMPICILLIN; C REACTIVE PROTEIN; CASPOFUNGIN; CD11B ANTIGEN; CD64 ANTIGEN; CEFAZOLIN; CLINDAMYCIN; COMPLEMENT; FLUCONAZOLE; GENTAMICIN; GLUTAMINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; LACTOFERRIN; MANNOSE BINDING LECTIN; MICAFUNGIN; MONOCLONAL ANTIBODY; PAGIBAXIMAB; PENICILLIN G; PLACEBO; PROBIOTIC AGENT; PROCALCITONIN; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VANCOMYCIN;

ADAPTIVE IMMUNITY; BLOOD CELL COUNT; CANDIDEMIA; CANDIDIASIS; CLINICAL FEATURE; DIAGNOSTIC PROCEDURE; ESCHERICHIA COLI; GENOMICS; HERPES SIMPLEX VIRUS; HUMAN; IMMUNE SYSTEM; INFECTION CONTROL; INFECTION PREVENTION; INFECTION RISK; INNATE IMMUNITY; LISTERIA MONOCYTOGENES; MORBIDITY; NEWBORN SEPSIS; NONHUMAN; PROTEOMICS; REVIEW; RISK FACTOR; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS AGALACTIAE;

ADAPTIVE IMMUNITY; ANTI-INFECTIVE AGENTS; ANTIBODIES, MONOCLONAL; ANTIFUNGAL AGENTS; BACTERIAL INFECTIONS; BIOLOGICAL MARKERS; BLOOD CELL COUNT; C-REACTIVE PROTEIN; CANDIDIASIS; ESCHERICHIA COLI INFECTIONS; FLUCONAZOLE; GENOMICS; HUMANS; IMMUNITY, INNATE; IMMUNOGLOBULINS, INTRAVENOUS; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES; LACTOFERRIN; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; PROTEOMICS; RISK FACTORS; SEPSIS; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS AGALACTIAE;

EID: 84875349819     PISSN: 00313955     EISSN: 15578240     Source Type: Journal    
DOI: 10.1016/j.pcl.2012.12.003     Document Type: Review

References (141)

1. Verani J.R., McGee L., Schrag S.J. Prevention of perinatal group B streptococcal disease-revised guidelines from CDC, 2010. MMWR Recomm Rep 2010, 59:1-36.
2. Stoll B.J., Hansen N., Fanaroff A.A., et al. Changes in pathogens causing early-onset sepsis in very-low-birth-weight infants. N Engl J Med 2002, 347:240-247.
3. Stoll B.J., Hansen N.I., Sanchez P.J., et al. Early onset neonatal sepsis: the burden of group B Streptococcal and E. coli disease continues. Pediatrics 2011, 127:817-826.
4. Weston E.J., Pondo T., Lewis M.M., et al. The burden of invasive early-onset neonatal sepsis in the United States, 2005-2008. Pediatr Infect Dis J 2011, 30:937-941.
5. Bizzarro M.J., Raskind C., Baltimore R.S., et al. Seventy-five years of neonatal sepsis at Yale: 1928-2003. Pediatrics 2005, 116:595-602.
6. Vergnano S., Menson E., Kennea N., et al. Neonatal infections in England: the NeonIN surveillance network. Arch Dis Child Fetal Neonatal Ed 2011, 96:F9-F14.
7. Stoll B.J., Hansen N., Fanaroff A.A., et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics 2002, 110:285-291.
8. Stoll B.J., Hansen N.I., Bell E.F., et al. Neonatal outcomes of extremely preterm infants from the NICHD Neonatal Research Network. Pediatrics 2010, 126:443-456.
9. Baker C.J., Byington C.L., Polin R.A. Policy statement-Recommendations for the prevention of perinatal group B streptococcal (GBS) disease. Pediatrics 2011, 128:611-616.
10. Kumar S., Ingle H., Prasad D.V., et al. Recognition of bacterial infection by innate immune sensors. Crit Rev Microbiol 2012, [Epub ahead of print].
11. Kollmann T.R., Crabtree J., Rein-Weston A., et al. Neonatal innate TLR-mediated responses are distinct from those of adults. J Immunol 2009, 183:7150-7160.
12. Belderbos M.E., Levy O., Stalpers F., et al. Neonatal plasma polarizes TLR4-mediated cytokine responses towards low IL-12p70 and high IL-10 production via distinct factors. PLoS One 2012, 7:e33419.
13. Carr R. Neutrophil production and function in newborn infants. Br J Haematol 2000, 110:18-28.
14. Levy O. Innate immunity of the newborn: basic mechanisms and clinical correlates. Nat Rev Immunol 2007, 7:379-390.
15. Guilmot A., Hermann E., Braud V.M., et al. Natural killer cell responses to infections in early life. J Innate Immun 2011, 3:280-288.
16. Schelonka R.L., Maheshwari A., Carlo W.A., et al. T cell cytokines and the risk of blood stream infection in extremely low birth weight infants. Cytokine 2011, 53:249-255.
17. Tolar J., Hippen K.L., Blazar B.R. Immune regulatory cells in umbilical cord blood: T regulatory cells and mesenchymal stromal cells. Br J Haematol 2009, 147:200-206.
18. Risdon G., Gaddy J., Horie M., et al. Alloantigen priming induces a state of unresponsiveness in human umbilical cord blood T cells. Proc Natl Acad Sci U S A 1995, 92:2413-2417.
19. Takahashi N., Kato H., Imanishi K., et al. Change of specific T cells in an emerging neonatal infectious disease induced by a bacterial superantigen. Microbiol Immunol 2009, 53:524-530.
20. Sautois B., Fillet G., Beguin Y. Comparative cytokine production by in vitro stimulated mononucleated cells from cord blood and adult blood. Exp Hematol 1997, 25:103-108.
21. Palmeira P., Quinello C., Silveira-Lessa A.L., et al. IgG placental transfer in healthy and pathological pregnancies. Clin Dev Immunol 2012, 2012:985646.
22. van den Berg J.P., Westerbeek E.A., van der Klis F.R., et al. Transplacental transport of IgG antibodies to preterm infants: a review of the literature. Early Hum Dev 2011, 87:67-72.
23. Malek A. Ex vivo human placenta models: transport of immunoglobulin G and its subclasses. Vaccine 2003, 21:3362-3364.
24. Malek A., Sager R., Kuhn P., et al. Evolution of maternofetal transport of immunoglobulins during human pregnancy. Am J Reprod Immunol 1996, 36:248-255.
25. Zandvoort A., Timens W. The dual function of the splenic marginal zone: essential for initiation of anti-TI-2 responses but also vital in the general first-line defense against blood-borne antigens. Clin Exp Immunol 2002, 130:4-11.
26. Brandtzaeg P. The mucosal immune system and its integration with the mammary glands. J Pediatr 2010, 156:S8-S15.
27. Hogasen A.K., Overlie I., Hansen T.W., et al. The analysis of the complement activation product SC5 b-9 is applicable in neonates in spite of their profound C9 deficiency. J Perinat Med 2000, 28:39-48.
28. Suzuki-Nishimura T., Uchida M.K. Binding of spin-labeled fatty acids and lysophospholipids to hydrophobic region of calmodulin. J Biochem 1991, 110:333-338.
29. Imperi M., Gherardi G., Berardi A., et al. Invasive neonatal GBS infections from an area-based surveillance study in Italy. Clin Microbiol Infect 2011, 17:1834-1839.
30. Tomlinson M.W., Schmidt N.M., Rourke J.W., et al. Rectovaginal Staphylococcus aureus colonization: is it a neonatal threat?. Am J Perinatol 2011, 28:673-676.
31. Yancey M.K., Duff P., Kubilis P., et al. Risk factors for neonatal sepsis. Obstet Gynecol 1996, 87:188-194.
32. Regan J.A., Klebanoff M.A., Nugent R.P., et al. Colonization with group B streptococci in pregnancy and adverse outcome. VIP Study Group. Am J Obstet Gynecol 1996, 174:1354-1360.
33. Schrag S.J., Zywicki S., Farley M.M., et al. Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis. N Engl J Med 2000, 342:15-20.
34. Tsai C.H., Chen Y.Y., Wang K.G., et al. Characteristics of early-onset neonatal sepsis caused by Escherichia coli. Taiwan J Obstet Gynecol 2012, 51:26-30.
35. Bizzarro M.J., Dembry L.M., Baltimore R.S., et al. Changing patterns in neonatal Escherichia coli sepsis and ampicillin resistance in the era of intrapartum antibiotic prophylaxis. Pediatrics 2008, 121:689-696.
36. Kaczmarek A., Budzynska A., Gospodarek E. Prevalence of genes encoding virulence factors among Escherichia coli with K1 antigen and non-K1 E. coli strains. J Med Microbiol 2012, 61(Pt 10):1360-1365.
37. Schrag S.J., Hadler J.L., Arnold K.E., et al. Risk factors for invasive, early-onset Escherichia coli infections in the era of widespread intrapartum antibiotic use. Pediatrics 2006, 118:570-576.
38. Al-Hasan M.N., Lahr B.D., Eckel-Passow J.E., et al. Antimicrobial resistance trends of Escherichia coli bloodstream isolates: a population-based study, 1998-2007. J Antimicrob Chemother 2009, 64:169-174.
39. Puopolo K.M., Eichenwald E.C. No change in the incidence of ampicillin-resistant, neonatal, early-onset sepsis over 18 years. Pediatrics 2010, 125:e1031-e1038.
40. Versalovic J. Manual of clinical microbiology 2012, ASM Press, Washington, DC. 10th edition.
41. Shetron-Rama L.M., Marquis H., Bouwer H.G., et al. Intracellular induction of Listeria monocytogenes actA expression. Infect Immun 2002, 70:1087-1096.
42. Moors M.A., Levitt B., Youngman P., et al. Expression of listeriolysin O and ActA by intracellular and extracellular Listeria monocytogenes. Infect Immun 1999, 67:131-139.
43. Smith B., Kemp M., Ethelberg S., et al. Listeria monocytogenes: maternal-foetal infections in Denmark 1994-2005. Scand J Infect Dis 2009, 41:21-25.
44. CDC From the Centers for Disease Control. Foodborne listeriosis-United States, 1988-1990. JAMA 1992, 267:2446-2448.
45. Schlech W.F. Foodborne listeriosis. Clin Infect Dis 2000, 31:770-775.
46. Miyairi I., Berlingieri D., Protic J., et al. Neonatal invasive group A streptococcal disease: case report and review of the literature. Pediatr Infect Dis J 2004, 23:161-165.
47. Prommalikit O., Mekmullica J., Pancharoen C., et al. Invasive pneumococcal infection in neonates: 3 case reports. J Med Assoc Thai 2010, 93(Suppl 5):S46-S48.
48. Malhotra A., Hunt R.W., Doherty R.R. Streptococcus pneumoniae sepsis in the newborn. J Paediatr Child Health 2012, 48:E79-E83.
49. Gomez M., Alter S., Kumar M.L., et al. Neonatal Streptococcus pneumoniae infection: case reports and review of the literature. Pediatr Infect Dis J 1999, 18:1014-1018.
50. Appelbaum P.C., Friedman Z., Fairbrother P.F., et al. Neonatal sepsis due to group G streptococci. Acta Paediatr Scand 1980, 69:559-562.
51. West P.W., Al-Sawan R., Foster H.A., et al. Speciation of presumptive viridans streptococci from early onset neonatal sepsis. J Med Microbiol 1998, 47:923-928.
52. Dobson S.R., Baker C.J. Enterococcal sepsis in neonates: features by age at onset and occurrence of focal infection. Pediatrics 1990, 85:165-171.
53. Ault K.A. Vaginal flora as the source for neonatal early onset Haemophilus influenzae sepsis. Pediatr Infect Dis J 1994, 13:243.
54. Hershckowitz S., Elisha M.B., Fleisher-Sheffer V., et al. A cluster of early neonatal sepsis and pneumonia caused by nontypable Haemophilus influenzae. Pediatr Infect Dis J 2004, 23:1061-1062.
55. Takala A.K., Pekkanen E., Eskola J. Neonatal Haemophilus influenzae infections. Arch Dis Child 1991, 66:437-440.
56. Didier C., Streicher M.P., Chognot D., et al. Late-onset neonatal infections: incidences and pathogens in the era of antenatal antibiotics. Eur J Pediatr 2012, 171:681-687.
57. Lim W.H., Lien R., Huang Y.C., et al. Prevalence and pathogen distribution of neonatal sepsis among very-low-birth-weight infants. Pediatr Neonatol 2012, 53:228-234.
58. Shane A.L., Hansen N.I., Stoll B.J., et al. Methicillin-resistant and susceptible Staphylococcus aureus bacteremia and meningitis in preterm infants. Pediatrics 2012, 129:e914-e922.
59. de Silva G.D., Kantzanou M., Justice A., et al. The ica operon and biofilm production in coagulase-negative Staphylococci associated with carriage and disease in a neonatal intensive care unit. J Clin Microbiol 2002, 40:382-388.
60. Drudy D., Mullane N.R., Quinn T., et al. Enterobacter sakazakii: an emerging pathogen in powdered infant formula. Clin Infect Dis 2006, 42:996-1002.
61. Tresoldi A.T., Padoveze M.C., Trabasso P., et al. Enterobacter cloacae sepsis outbreak in a newborn unit caused by contaminated total parenteral nutrition solution. Am J Infect Control 2000, 28:258-261.
62. Cohen-Wolkowiez M., Moran C., Benjamin D.K., et al. Early and late onset sepsis in late preterm infants. Pediatr Infect Dis J 2009, 28:1052-1056.
63. Bell Y., Barton M., Thame M., et al. Neonatal sepsis in Jamaican neonates. Ann Trop Paediatr 2005, 25:293-296.
64. Leibovitz E., Flidel-Rimon O., Juster-Reicher A., et al. Sepsis at a neonatal intensive care unit: a four-year retrospective study (1989-1992). Isr J Med Sci 1997, 33:734-738.
65. Townsend S., Hurrell E., Forsythe S. Virulence studies of Enterobacter sakazakii isolates associated with a neonatal intensive care unit outbreak. BMC Microbiol 2008, 8:64.
66. Etuwewe O., Kulshrestha R., Sangra M., et al. Brain abscesses due to Citrobacter koseri in a pair of twins. Pediatr Infect Dis J 2009, 28:1035.
67. Townsend S.M., Pollack H.A., Gonzalez-Gomez I., et al. Citrobacter koseri brain abscess in the neonatal rat: survival and replication within human and rat macrophages. Infect Immun 2003, 71:5871-5880.
68. Benjamin D.K., Stoll B.J., Fanaroff A.A., et al. Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months. Pediatrics 2006, 117:84-92.
69. Neu N., Malik M., Lunding A., et al. Epidemiology of candidemia at a children's hospital, 2002 to 2006. Pediatr Infect Dis J 2009, 28:806-809.
70. Chitnis A.S., Magill S.S., Edwards J.R., et al. Trends in Candida central line-associated bloodstream infections among NICUs, 1999-2009. Pediatrics 2012, 130:e46-e52.
71. Bliss J.M., Wong A.Y., Bhak G., et al. Candida virulence properties and adverse clinical outcomes in neonatal candidiasis. J Pediatr 2012, 161:441-447.e2.
72. Stoll B.J., Hansen N., Fanaroff A.A., et al. To tap or not to tap: high likelihood of meningitis without sepsis among very low birth weight infants. Pediatrics 2004, 113:1181-1186.
73. Jawaheer G., Neal T.J., Shaw N.J. Blood culture volume and detection of coagulase negative staphylococcal septicaemia in neonates. Arch Dis Child Fetal Neonatal Ed 1997, 76:F57-F58.
74. Neal P.R., Kleiman M.B., Reynolds J.K., et al. Volume of blood submitted for culture from neonates. J Clin Microbiol 1986, 24:353-356.
75. Visser V.E., Hall R.T. Urine culture in the evaluation of suspected neonatal sepsis. J Pediatr 1979, 94:635-638.
76. Wiswell T.E., Baumgart S., Gannon C.M., et al. No lumbar puncture in the evaluation for early neonatal sepsis: will meningitis be missed?. Pediatrics 1995, 95:803-806.
77. Lakeman F.D., Whitley R.J. Diagnosis of herpes simplex encephalitis: application of polymerase chain reaction to cerebrospinal fluid from brain-biopsied patients and correlation with disease. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. J Infect Dis 1995, 171:857-863.
78. Simko J.P., Caliendo A.M., Hogle K., et al. Differences in laboratory findings for cerebrospinal fluid specimens obtained from patients with meningitis or encephalitis due to herpes simplex virus (HSV) documented by detection of HSV DNA. Clin Infect Dis 2002, 35:414-419.
79. Christensen R.D., Rothstein G., Hill H.R., et al. Fatal early onset group B streptococcal sepsis with normal leukocyte counts. Pediatr Infect Dis 1985, 4:242-245.
80. Hornik C.P., Benjamin D.K., Becker K.C., et al. Use of the complete blood cell count in early-onset neonatal sepsis. Pediatr Infect Dis J 2012, 31:799-802.
81. Murphy K., Weiner J. Use of leukocyte counts in evaluation of early-onset neonatal sepsis. Pediatr Infect Dis J 2012, 31:16-19.
82. Tillett W.S., Francis T. Serological reactions in pneumonia with a non-protein somatic fraction of pneumococcus. J Exp Med 1930, 52:561-571.
83. Hengst J.M. The role of C-reactive protein in the evaluation and management of infants with suspected sepsis. Adv Neonatal Care 2003, 3:3-13.
84. Philip A.G., Mills P.C. Use of C-reactive protein in minimizing antibiotic exposure: experience with infants initially admitted to a well-baby nursery. Pediatrics 2000, 106:E4.
85. Chiesa C., Signore F., Assumma M., et al. Serial measurements of C-reactive protein and interleukin-6 in the immediate postnatal period: reference intervals and analysis of maternal and perinatal confounders. Clin Chem 2001, 47:1016-1022.
86. Forest J.C., Lariviere F., Dolce P., et al. C-reactive protein as biochemical indicator of bacterial infection in neonates. Clin Biochem 1986, 19:192-194.
87. Chiesa C., Natale F., Pascone R., et al. C reactive protein and procalcitonin: reference intervals for preterm and term newborns during the early neonatal period. Clin Chim Acta 2011, 412:1053-1059.
88. Hofer N., Muller W., Resch B. Non-infectious conditions and gestational age influence C-reactive protein values in newborns during the first 3 days of life. Clin Chem Lab Med 2011, 49:297-302.
89. Auriti C., Fiscarelli E., Ronchetti M.P., et al. Procalcitonin in detecting neonatal nosocomial sepsis. Arch Dis Child Fetal Neonatal Ed 2012, 97:F368-F370.
90. Vouloumanou E.K., Plessa E., Karageorgopoulos D.E., et al. Serum procalcitonin as a diagnostic marker for neonatal sepsis: a systematic review and meta-analysis. Intensive Care Med 2011, 37:747-762.
91. Neth O., Jack D.L., Dodds A.W., et al. Mannose-binding lectin binds to a range of clinically relevant microorganisms and promotes complement deposition. Infect Immun 2000, 68:688-693.
92. Ozkan H., Koksal N., Cetinkaya M., et al. Serum mannose-binding lectin (MBL) gene polymorphism and low MBL levels are associated with neonatal sepsis and pneumonia. J Perinatol 2012, 32:210-217.
93. Ng P.C., Li K., Wong R.P., et al. Proinflammatory and anti-inflammatory cytokine responses in preterm infants with systemic infections. Arch Dis Child Fetal Neonatal Ed 2003, 88:F209-F213.
94. Resch B., Gusenleitner W., Muller W.D. Procalcitonin and interleukin-6 in the diagnosis of early-onset sepsis of the neonate. Acta Paediatr 2003, 92:243-245.
95. Genel F., Atlihan F., Gulez N., et al. Evaluation of adhesion molecules CD64, CD11b and CD62L in neutrophils and monocytes of peripheral blood for early diagnosis of neonatal infection. World J Pediatr 2012, 8:72-75.
96. Pammi M., Brocklehurst P. Granulocyte transfusions for neonates with confirmed or suspected sepsis and neutropenia. Cochrane Database Syst Rev 2011, (10). CD003956.
97. Ng P.C., Ang I.L., Chiu R.W., et al. Host-response biomarkers for diagnosis of late-onset septicemia and necrotizing enterocolitis in preterm infants. J Clin Invest 2010, 120:2989-3000.
98. Daniels J.P., Gray J., Pattison H.M., et al. Intrapartum tests for group B streptococcus: accuracy and acceptability of screening. BJOG 2011, 118:257-265.
99. Polin R.A., Denson S., Brady M.T. Strategies for prevention of health care-associated infections in the NICU. Pediatrics 2012, 129:e1085-e1093.
100. Kilbride H.W., Wirtschafter D.D., Powers R.J., et al. Implementation of evidence-based potentially better practices to decrease nosocomial infections. Pediatrics 2003, 111:e519-e533.
101. Bloom B.T., Craddock A., Delmore P.M., et al. Reducing acquired infections in the NICU: observing and implementing meaningful differences in process between high and low acquired infection rate centers. J Perinatol 2003, 23:489-492.
102. Andersen C., Hart J., Vemgal P., et al. Prospective evaluation of a multi-factorial prevention strategy on the impact of nosocomial infection in very-low-birthweight infants. J Hosp Infect 2005, 61:162-167.
103. Shah P., Shah V. Continuous heparin infusion to prevent thrombosis and catheter occlusion in neonates with peripherally placed percutaneous central venous catheters. Cochrane Database Syst Rev 2005, (3). CD002772.
104. Birch P., Ogden S., Hewson M. A randomised, controlled trial of heparin in total parenteral nutrition to prevent sepsis associated with neonatal long lines: the Heparin in Long Line Total Parenteral Nutrition (HILLTOP) trial. Arch Dis Child Fetal Neonatal Ed 2010, 95:F252-F257.
105. Fanaroff A.A., Korones S.B., Wright L.L., et al. A controlled trial of intravenous immune globulin to reduce nosocomial infections in very-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. N Engl J Med 1994, 330:1107-1113.
106. Ohlsson A., Lacy J. Intravenous immunoglobulin for suspected or subsequently proven infection in neonates. Cochrane Database Syst Rev 2010, (3). CD001239.
107. Brocklehurst P., Farrell B., King A., et al. Treatment of neonatal sepsis with intravenous immune globulin. N Engl J Med 2011, 365:1201-1211.
108. Vernachio J., Bayer A.S., Le T., et al. Anti-clumping factor A immunoglobulin reduces the duration of methicillin-resistant Staphylococcus aureus bacteremia in an experimental model of infective endocarditis. Antimicrob Agents Chemother 2003, 47:3400-3406.
109. Patti J.M., Allen B.L., McGavin M.J., et al. MSCRAMM-mediated adherence of microorganisms to host tissues. Annu Rev Microbiol 1994, 48:585-617.
110. Weisman L.E., Thackray H.M., Steinhorn R.H., et al. A randomized study of a monoclonal antibody (pagibaximab) to prevent staphylococcal sepsis. Pediatrics 2011, 128:271-279.
111. Benjamin D.K., Schelonka R., White R., et al. A blinded, randomized, multicenter study of an intravenous Staphylococcus aureus immune globulin. J Perinatol 2006, 26:290-295.
112. Bloom B., Schelonka R., Kueser T., et al. Multicenter study to assess safety and efficacy of INH-A21, a donor-selected human staphylococcal immunoglobulin, for prevention of nosocomial infections in very low birth weight infants. Pediatr Infect Dis J 2005, 24:858-866.
113. Shah P.S., Kaufman D.A. Antistaphylococcal immunoglobulins to prevent staphylococcal infection in very low birth weight infants. Cochrane Database Syst Rev 2009, (2). CD006449.
114. Carr R., Brocklehurst P., Dore C.J., et al. Granulocyte-macrophage colony stimulating factor administered as prophylaxis for reduction of sepsis in extremely preterm, small for gestational age neonates (the PROGRAMS trial): a single-blind, multicentre, randomised controlled trial. Lancet 2009, 373:226-233.
115. Poindexter B.B., Ehrenkranz R.A., Stoll B.J., et al. Effect of parenteral glutamine supplementation on plasma amino acid concentrations in extremely low-birth-weight infants. Am J Clin Nutr 2003, 77:737-743.
116. Tubman T.R., Thompson S.W., McGuire W. Glutamine supplementation to prevent morbidity and mortality in preterm infants. Cochrane Database Syst Rev 2008, (1). CD001457.
117. Alfaleh K., Anabrees J., Bassler D., et al. Probiotics for prevention of necrotizing enterocolitis in preterm infants. Cochrane Database Syst Rev 2011, (3). CD005496.
118. Bonsante F., Iacobelli S., Gouyon J.B. Routine probiotic use in very preterm infants: retrospective comparison of two cohorts. Am J Perinatol 2012, [Epub ahead of print].
119. Deshpande G., Rao S., Patole S., et al. Updated meta-analysis of probiotics for preventing necrotizing enterocolitis in preterm neonates. Pediatrics 2010, 125:921-930.
120. Manzoni P., Rinaldi M., Cattani S., et al. Bovine lactoferrin supplementation for prevention of late-onset sepsis in very low-birth-weight neonates: a randomized trial. JAMA 2009, 302:1421-1428.
121. Kaufman D., Boyle R., Hazen K.C., et al. Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N Engl J Med 2001, 345:1660-1666.
122. Manzoni P., Stolfi I., Pugni L., et al. A multicenter, randomized trial of prophylactic fluconazole in preterm neonates. N Engl J Med 2007, 356:2483-2495.
123. Kaufman D.A., Cuff A.L., Wamstad J.B., et al. Fluconazole prophylaxis in extremely low birth weight infants and neurodevelopmental outcomes and quality of life at 8 to 10 years of age. J Pediatr 2011, 158:759-765.e1.
124. Kicklighter S.D., Springer S.C., Cox T., et al. Fluconazole for prophylaxis against candidal rectal colonization in the very low birth weight infant. Pediatrics 2001, 107:293-298.
125. Healy C.M., Campbell J.R., Zaccaria E., et al. Fluconazole prophylaxis in extremely low birth weight neonates reduces invasive candidiasis mortality rates without emergence of fluconazole-resistant Candida species. Pediatrics 2008, 121:703-710.
126. Pappas P.G., Kauffman C.A., Andes D., et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009, 48:503-535.
127. Cotten C.M., Taylor S., Stoll B., et al. Prolonged duration of initial empirical antibiotic treatment is associated with increased rates of necrotizing enterocolitis and death for extremely low birth weight infants. Pediatrics 2009, 123:58-66.
128. Kuppala V.S., Meinzen-Derr J., Morrow A.L., et al. Prolonged initial empirical antibiotic treatment is associated with adverse outcomes in premature infants. J Pediatr 2011, 159:720-725.
129. Arslan U., Erayman I., Kirdar S., et al. Serratia marcescens sepsis outbreak in a neonatal intensive care unit. Pediatr Int 2010, 52:208-212.
130. Dashti A.A., Jadaon M.M., Gomaa H.H., et al. Transmission of a Klebsiella pneumoniae clone harbouring genes for CTX-M-15-like and SHV-112 enzymes in a neonatal intensive care unit of a Kuwaiti hospital. J Med Microbiol 2010, 59:687-692.
131. Golan Y., Doron S., Sullivan B., et al. Transmission of vancomycin-resistant enterococcus in a neonatal intensive care unit. Pediatr Infect Dis J 2005, 24:566-567.
132. Linkin D.R., Fishman N.O., Patel J.B., et al. Risk factors for extended-spectrum beta-lactamase-producing Enterobacteriaceae in a neonatal intensive care unit. Infect Control Hosp Epidemiol 2004, 25:781-783.
133. Maraki S., Scoulica E., Manoura A., et al. Chryseobacterium meningosepticum colonization outbreak in a neonatal intensive care unit. Eur J Clin Microbiol Infect Dis 2009, 28:1415-1419.
134. Touati A., Achour W., Cherif A., et al. Outbreak of Acinetobacter baumannii in a neonatal intensive care unit: antimicrobial susceptibility and genotyping analysis. Ann Epidemiol 2009, 19:372-378.
135. Patel S.J., Oshodi A., Prasad P., et al. Antibiotic use in neonatal intensive care units and adherence with Centers for Disease Control and Prevention 12 Step Campaign to Prevent Antimicrobial Resistance. Pediatr Infect Dis J 2009, 28:1047-1051.
136. Tamma P.D., Cosgrove S.E. Antimicrobial stewardship. Infect Dis Clin North Am 2011, 25:245-260.
137. Patel S.J., Saiman L., Duchon J.M., et al. Development of an antimicrobial stewardship intervention using a model of actionable feedback. Interdiscip Perspect Infect Dis 2012, 2012:150367.
138. Chen S.C., Slavin M.A., Sorrell T.C. Echinocandin antifungal drugs in fungal infections: a comparison. Drugs 2011, 71:11-41.
139. Smith P.B., Walsh T.J., Hope W., et al. Pharmacokinetics of an elevated dosage of micafungin in premature neonates. Pediatr Infect Dis J 2009, 28:412-415.
140. Heresi G.P., Gerstmann D.R., Reed M.D., et al. The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants. Pediatr Infect Dis J 2006, 25:1110-1115.
141. Benjamin D.K., Smith P.B., Arrieta A., et al. Safety and pharmacokinetics of repeat-dose micafungin in young infants. Clin Pharmacol Ther 2010, 87:93-99.